Effects of reperfusion grade and reperfusion strategy on the clinical outcome: Insights from ESCAPE-NA1 trial.

Ischemic stroke endovascular treatment first-pass effect mechanical thrombectomy reperfusion grade

Journal

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
ISSN: 2385-2011
Titre abrégé: Interv Neuroradiol
Pays: United States
ID NLM: 9602695

Informations de publication

Date de publication:
14 Oct 2024
Historique:
medline: 14 10 2024
pubmed: 14 10 2024
entrez: 14 10 2024
Statut: aheadofprint

Résumé

We evaluated the association of reperfusion quality and different patterns of achieved reperfusion with clinical and radiological outcomes in the ESCAPE NA1 trial. Data are from the ESCAPE-NA1 trial. Good clinical outcome [90-day modified Rankin Scale (mRS) 0-2], excellent outcome (90-day mRS0-1), isolated subarachnoid hemorrhage, symptomatic hemorrhage (sICH) on follow-up imaging, and death were compared across different levels of reperfusion defined by expanded Treatment in Cerebral Infarction (eTICI) Scale. Comparisons were also made between patients with (a) first-pass eTICI 2c3 reperfusion vs multiple-pass eTICI 2c3; (b) final eTICI 2b reperfusion vs eTICI 2b converted-to-eTICI 2c3; (c) sudden reperfusion vs gradual reperfusion if >1 pass was required. Multivariable logistic regression was used to test associations of reperfusion grade and clinical outcomes. Of 1037 included patients, final eTICI 0-1 was achieved in 46 (4.4%), eTICI 2a in 76 (7.3%), eTICI 2b in 424 (40.9%), eTICI 2c in 284 (27.4%), and eTICI 3 in 207 (20%) patients. The odds for good and excellent clinical outcome gradually increased with improved reperfusion grades (adjOR ranging from 5.7-29.3 and 4.3-17.6) and decreased for sICH and death. No differences in outcomes between first-pass versus multiple-pass eTICI 2c3, eTICI 2b converted-to-eTICI 2c3 versus unchanged eTICI 2b and between sudden versus gradual eTICI 2c3 reperfusion were observed. Better reperfusion degrees significantly improved clinical outcomes and reduced mortality, independent of the number of passes and whether eTICI 2c3 was achieved suddenly or gradually.

Sections du résumé

BACKGROUND BACKGROUND
We evaluated the association of reperfusion quality and different patterns of achieved reperfusion with clinical and radiological outcomes in the ESCAPE NA1 trial.
METHODS METHODS
Data are from the ESCAPE-NA1 trial. Good clinical outcome [90-day modified Rankin Scale (mRS) 0-2], excellent outcome (90-day mRS0-1), isolated subarachnoid hemorrhage, symptomatic hemorrhage (sICH) on follow-up imaging, and death were compared across different levels of reperfusion defined by expanded Treatment in Cerebral Infarction (eTICI) Scale. Comparisons were also made between patients with (a) first-pass eTICI 2c3 reperfusion vs multiple-pass eTICI 2c3; (b) final eTICI 2b reperfusion vs eTICI 2b converted-to-eTICI 2c3; (c) sudden reperfusion vs gradual reperfusion if >1 pass was required. Multivariable logistic regression was used to test associations of reperfusion grade and clinical outcomes.
RESULTS RESULTS
Of 1037 included patients, final eTICI 0-1 was achieved in 46 (4.4%), eTICI 2a in 76 (7.3%), eTICI 2b in 424 (40.9%), eTICI 2c in 284 (27.4%), and eTICI 3 in 207 (20%) patients. The odds for good and excellent clinical outcome gradually increased with improved reperfusion grades (adjOR ranging from 5.7-29.3 and 4.3-17.6) and decreased for sICH and death. No differences in outcomes between first-pass versus multiple-pass eTICI 2c3, eTICI 2b converted-to-eTICI 2c3 versus unchanged eTICI 2b and between sudden versus gradual eTICI 2c3 reperfusion were observed.
CONCLUSION CONCLUSIONS
Better reperfusion degrees significantly improved clinical outcomes and reduced mortality, independent of the number of passes and whether eTICI 2c3 was achieved suddenly or gradually.

Identifiants

pubmed: 39397754
doi: 10.1177/15910199241288874
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15910199241288874

Déclaration de conflit d'intérêts

Declaration of conflicting interestThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:

Auteurs

Petra Cimflova (P)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Department of Radiology, University of Calgary, Calgary, Alberta, Canada.
Department of Medical Imaging, St. Anne's University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Diagnostic and Interventional Neuroradiology, Inselspital, University Hospital Bern, Bern, Switzerland.

Johanna M Ospel (JM)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Department of Radiology, University of Calgary, Calgary, Alberta, Canada.

Nishita Singh (N)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Department of Internal Medicine-Neurology Division, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

Martha Marko (M)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Department of Neurology, Medical University of Vienna, Vienna, Austria.

Nima Kashani (N)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Department of Radiology, Rady Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Arnuv Mayank (A)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.

Andrew Demchuk (A)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Bijoy Menon (B)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Alexandre Y Poppe (AY)

Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

Raul Nogueira (R)

UPMC Stroke Institute, Department of Neurology and Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Ryan McTaggart (R)

Warren Alpert School of Medicine, Brown University, Providence, RI, USA.

Jeremy L Rempel (JL)

University of Alberta Hospital, Edmonton, Alberta, Canada.

Michael Tymianski (M)

NoNO, Toronto, Ontario, Canada.

Michael D Hill (MD)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Mohammed A Almekhlafi (MA)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Mayank Goyal (M)

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Classifications MeSH